3 completed, 3 recruiting, 2 unknown. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Recruiting 3, Unknown 2 |
| Phase 2 | 4 | Unknown 2, Completed 1, Recruiting 1 |
Follow Metastatic Sarcoma: new trials by email Literature Review of Metastatic Sarcoma trials Research Report on Metastatic Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer 64Cu-LNTH-1363S - Metastatic Sarcoma, Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Lantheus Medical Imaging | 26 | 2025-08-01 | 2025-08-12 |
| Safety and Feasibility of Intraoperative Visualization With Cytalux in Children Cytalux - Osteosarcoma, Pulmonary Metastasis | Phase 1 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 10 | 2024-04-08 | 2026-11-12 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-04 |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma YH001, Envafolimab, Doxorubicin - Advanced Sarcoma, Metastatic Sarcoma | Phase 1 / Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 15 | 2022-11-14 | 2023-09-21 |
| Mix Vaccine for Metastatic Sarcoma Patients Mix vaccine - Metastatic Sarcoma, Reaction - Mixed Vaccine | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2017-11-30 | 2019-09-12 |
| Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma NC 6300 - Solid Tumor, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Unknown | NanoCarrier Co., Ltd. | 150 | 2017-06-30 | 2020-02-28 |
| α-TEA in Advanced Cancer 2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA - Metastatic Carcinoma, Metastatic Sarcoma | Phase 1 | Completed | Providence Health & Services | 17 | 2014-08-04 | 2018-08-17 |
| Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid - Sarcoma, Soft Tissue Sarcoma | Phase 1 | Completed | Mohammed M Milhem | 47 | 2010-09-01 | 2018-08-10 |
Sarcoma (8) · Carcinoma (1) · Chondrosarcoma (1) · Colorectal Neoplasms (1) · Dermatofibrosarcoma (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Liposarcoma (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Pancreatic Neoplasms (1) · Sarcoma, Synovial (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Connective and Soft Tissue (8) · Neoplasms, Connective Tissue (3) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Esophageal Diseases (1) · Fibrosarcoma (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Hemic and Lymphatic Diseases (1)
Doxorubicin (2) · 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid (1) · Bevacizumab (1) · Biopsy (1) · Docetaxel (1) · Gemcitabine (1) · Immunotherapy, Active (1) · Magnetic Resonance Spectroscopy (1) · NC 6300 (1) · Pafolacianine (1) · Specimen Handling (1) · Valproic Acid (1) · envafolimab (1) · liposomal doxorubicin (1) · peposertib (1)
Ann & Robert H Lurie Children's Hospital of Chicago (1) · Fuda Cancer Hospital, Guangzhou (1) · Lantheus Medical Imaging (1) · Mohammed M Milhem (1) · NanoCarrier Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Providence Health & Services (1) · Tracon Pharmaceuticals Inc. (1)
United States (7) · China (1)
Atsushi Osada (1) · Brendan Curti, MD (1) · Candace L Haddox (1) · James Freddo, MD (1) · Mohammed Milhem, MD (1) · Timothy Lautz, MD (1)
UM1CA186709 (1)